Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Sells $55,566.16 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Day One Biopharmaceuticals Trading Up 1.6 %

DAWN stock opened at $12.43 on Friday. The company has a market capitalization of $1.25 billion, a P/E ratio of -12.07 and a beta of -1.46. The business has a 50 day simple moving average of $12.37 and a 200-day simple moving average of $13.47. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.13 and a twelve month high of $18.07.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Bank of America cut their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Finally, The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $35.71.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. GF Fund Management CO. LTD. purchased a new stake in Day One Biopharmaceuticals during the 4th quarter valued at approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Day One Biopharmaceuticals by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,579 shares of the company’s stock valued at $958,000 after purchasing an additional 10,386 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $380,000. Stonepine Capital Management LLC lifted its holdings in shares of Day One Biopharmaceuticals by 14.3% during the fourth quarter. Stonepine Capital Management LLC now owns 235,000 shares of the company’s stock worth $2,977,000 after purchasing an additional 29,325 shares during the period. Finally, Tema Etfs LLC purchased a new position in Day One Biopharmaceuticals in the 4th quarter valued at $1,087,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.